Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Apr 1;66(4):516-524.
doi: 10.2967/jnumed.124.268499.

Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer

Pierre Vera  1 , Philippe Giraud  2 , Sébastien Hapdey  3 , Pierrick Gouel  3 , Orianne Jan  3 , Paul Le Roux  3 , Alexandra Langlais  4 , Emilie Lévêque  5 , Florence Le Tinier  6 , Anaïs Olivier  7 , Etienne Martin  8 , Alina Berriolo-Riedinger  9 , Nicolas Pourel  10 , Jean Marc Broglia  11 , Pierre Boisselier  12 , Sophie Guillemard  13 , Naji Salem  14 , Isabelle Brenot-Rossi  15 , Camilo Garcia  16 , Céline Berthold  17 , Etienne Giroux-Leprieur  18 , Damien Moreau  19 , Sophie Guillerm  20 , Khadija Benali  21 , Laurent Tessonnier  22 , Clarisse Audigier-Valette  23 , Delphine Lerouge  24 , Elske Quak  25 , Carole Massabeau  26 , Frédéric Courbon  27 , Maxime Loo  28 , Anne Larrouy  29 , Nadia Ghazzar  30 , Philippe Chaumet-Riffaud  31 , Elodie Amour  4 , Gérard Zalcman  32 , Romain Modzelewski  3 , Sébastien Thureau  33
Affiliations
Clinical Trial

Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer

Pierre Vera et al. J Nucl Med. .

Abstract

The purpose of this study was to assess the prognostic value of 18F-FDG PET parameter variation between baseline and 42 Gy (PET2) of radiochemotherapy at 6 mo and 1 y of evaluation in patients with stage III inoperable nonsmall cell lung cancer based on RECIST 1.1. Methods: In total, 158 patients in a prospective multicenter phase II/III study were analyzed. Patients were randomized into 2 groups: an experimental arm (group A) and a standard arm (group B). Patients from group A with residual metabolism on PET2 (group A+) at 42 Gy received a radiation boost (74 Gy). Patients without residual uptake on 18F-FDG PET at 42 Gy (group A-) and patients in group B received a standard radiotherapy dose (66 Gy). We compared group A with group B. The 18F-FDG PET parameters SUVmax, SUVmean, SUVpeak, peak SUV normalized on lean body mass, mean SUV normalized on lean body mass, total lesion glycolysis, total metabolic tumor volume (MTV) (tumor and nodes), and tumor MTV were measured. All patients were evaluated with RECIST 1.1 using CT at 6 mo and 1 y after radiochemotherapy. Progression-free survival and overall survival were evaluated. Results: Except for the radiotherapy dose (P < 0.001), patient demographic characteristics were similar between the 2 groups (A vs. B). All 18F-FDG PET uptake and volume parameter measurements were correlated. Therefore, only the change in SUVmax (ΔSUVmax) and total MTV were selected for the analysis. There was no significant difference in any variable between the 2 groups. In the multivariate analysis, ΔSUVmax appeared to be the most important prognostic factor for overall survival, and SUVmax of PET2 appeared to be the most important prognostic factor for progression-free survival. Conclusion: 18F-FDG PET at 42 Gy can be used to identify good responders to radiochemotherapy in patients with inoperable stage III nonsmall cell lung cancer. The SUVmax of PET2 and ΔSUVmax are independent prognostic factors.

Keywords: 18F-FDG PET; nonsmall cell lung cancer; radiochemotherapy.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources